Business activity: complete technological cycle of production of genetically engineered insulins from substance to finished dosage forms. Production by own technology of the whole spectrum of human insulin preparations recombinant.
Facilities: the capacity of Kyiv’s Indar insulin plant allows the production of 13-15 million bottles of the drug per year. The only producer of animal insulin in Ukraine.
Average number of employees: 300
Land plot: no data
Legal obligations: no data
Additional information: Main markets: Ukraine, Moldova, Kazakhstan, CIS, Brazil and others.
Share proposed for privatization: 70,7016%
Starting price: ТВС
Investment advisor: not selected